HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis.
Jennifer M LundKristina BrolidenMaria N PyraKatherine K ThomasDeborah DonnellElizabeth IrunguTimothy R MuwongeNelly MugoMadhuri ManoharMarianne JanssonRomel MackelprangMark A MarzinkeJared M BaetenJairam R LingappaPublished in: Journal of virology (2016)
Although there is not yet an effective HIV-1 vaccine, PrEP for at-risk HIV-1-uninfected individuals is a highly efficacious intervention to prevent HIV-1 acquisition and is currently being recommended by the CDC and WHO for all individuals at high risk of HIV-1 acquisition. We previously demonstrated that PrEP use does not enhance peripheral blood HIV-1-specific T-cell responses in HIV-exposed individuals. Here, we evaluate for cervicovaginal HIV-neutralizing IgA responses in genital mucosal secretions of HIV-exposed women, which is likely a more relevant site than peripheral blood for observation of potentially protective immune events occurring in response to sexual HIV-1 exposure for various periods. Furthermore, we assess for host response in the context of longitudinal quantification of HIV-1 exposure. We report that HIV-neutralizing IgA is significantly correlated with higher HIV-1 exposure and, furthermore, that there are more women with HIV-1-neutralizing IgA in the on-PrEP group than in the placebo group.
Keyphrases
- antiretroviral therapy
- hiv positive
- hiv infected
- hiv testing
- men who have sex with men
- human immunodeficiency virus
- hiv aids
- hepatitis c virus
- south africa
- peripheral blood
- randomized controlled trial
- adipose tissue
- pregnant women
- clinical trial
- zika virus
- polycystic ovary syndrome
- type diabetes
- cell proliferation
- cross sectional
- phase iii